Modelled DT Structure
Method: homology modeling
Template PDB: 6F34_A
Identity: 37.587%
Minimized Score: -1066.647 kcal/mol
Detail: Structure Info
| General Information of DT | |||||
|---|---|---|---|---|---|
| DT ID | DTD0468 | ||||
| Gene Name | SLC7A2 | ||||
| Protein Name | Cationic amino acid transporter 2 | ||||
| Gene ID | |||||
| UniProt ID | |||||
| TCDB ID | |||||
| 3D Structure |
Modelled DT Structure Method: homology modeling Template PDB: 6F34_A Identity: 37.587% Minimized Score: -1066.647 kcal/mol Detail: Structure Info |
||||
| Synonyms | ATRC2; CAT-2; CAT2; HCAT2; Low affinity cationic amino acid transporter 2; SLC7A2; Solute carrier family 7 member 2 | ||||
| DT Family | Amino Acid-Polyamine-Organocation (APC) Family | ||||
| Cationic Amino Acid Transporter (CAT) Family | |||||
| Tissue Specificity | Expressed at high levels in the skeletalmuscle, placenta and ovary. Expressed at intermediate levels inthe liver and pancreas and at low levels in the kidney and heart. | ||||
| Function | This transporter functions as permease involved in the transport of the cationic amino acids (arginine, lysine and ornithine); the affinity for its substrates differs between isoforms created by alternative splicing. Isoform 1 functions as permease that mediates the transport of the cationic amino acids (arginine, lysine and ornithine), and it has much higher affinity for arginine than isoform 2. Isoform 2 functions as low-affinity, high capacity permease involved in the transport of the cationic amino acids (arginine, lysine and ornithine). | ||||
| Endogenous Substrate(s) | Arginine; Lysine; Ornithine | ||||
| Variability Data of This Drug Transporter (DT) | |||||
|
Regulatory Variability Data of This DT (VARIDT 3.0) |
|||||
|
(β) Post-translational Modification of This DT |
|||||
|
(γ) Transcriptional Regulation of This DT |
|||||
|
(δ) Epigenetic Regulation of This DT |
|||||
|
Structural Variability Data of This DT (VARIDT 2.0) |
|||||
|
(β) Inter-species Structural Differences |
|||||
|
General Variability Data of This DT (VARIDT 1.0) |
|||||
|
(β) Disease-specific Protein Abundances of This DT |
|||||
|
(γ) Species- and Tissue-specific DT Abundances |
|||||
| Molecular Transporting Profile of This DT | |||||
|
Full List of Drug(s) Transported by This DT |
|||||
|
Withdrawn, Discontinued or Preclinical Drug |
Click to Show/Hide the Full List of Drug: 1 Drugs in Total | ||||
| Drug Name | Highest Status | Detail | Indication | ICD 11 | Ref |
|
L-ornithine
|
Preclinical | Drug Info | Immunomodulatory and wound-healing | EL8Y | [1] |
|
Endogenous Metabolites (EMs) Handled by This DT |
|||||
|
Endogenous Metabolites (EMs) |
Click to Show/Hide the Full List of EMs: 1 EMs in Total | ||||
| EM Name | PubChem CID | Detail | Experimental Material | Ref | |
| Arginine | EM Info | Identified using Slc7a2 knockout mice | [2] | ||
| References | |||||
| 1 | Genetic basis for plasma amino acid concentrations based on absolute quantification: a genome-wide association study in the Japanese population. Eur J Hum Genet. 2019 Apr;27(4):621-630. | ||||
| 2 | Macrophages require distinct arginine catabolism and transport systems for proliferation and for activation. Eur J Immunol. 2006 Jun;36(6):1516-26. | ||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.